| 000 | 01716 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516150520.0 | ||
| 264 | 0 | _c20130726 | |
| 008 | 201307s 0 0 eng d | ||
| 022 | _a1532-1827 | ||
| 024 | 7 |
_a10.1038/bjc.2013.227 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMillward, M | |
| 245 | 0 | 0 |
_aPhase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cMay 2013 |
||
| 300 |
_a1998-2004 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 | _aDisease Progression |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aOligodeoxyribonucleotides _xadministration & dosage |
| 650 | 0 | 4 |
_aSkin Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aUnderhill, C | |
| 700 | 1 | _aLobb, S | |
| 700 | 1 | _aMcBurnie, J | |
| 700 | 1 | _aMeech, S J | |
| 700 | 1 | _aGomez-Navarro, J | |
| 700 | 1 | _aMarshall, M A | |
| 700 | 1 | _aHuang, B | |
| 700 | 1 | _aMather, C B | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 108 _gno. 10 _gp. 1998-2004 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bjc.2013.227 _zAvailable from publisher's website |
| 999 |
_c22732142 _d22732142 |
||